Advancing a Safe, Chronic Therapy for Gastroparesis

Approach

CinDome Pharma, a CinRx portfolio company, is advancing deudomperidone (CIN-102) for the treatment of chronic gastroparesis. Gastroparesis, or delayed gastric emptying, occurs when the stomach does not empty normally, causing abdominal discomfort, severe nausea, or vomiting after eating. These symptoms can be hard to manage and lead to other complications.

An estimated 12-16 million people in the United States alone experience symptoms of gastroparesis and there is no long-term treatment for this debilitating condition. The incidence is growing on pace with type 2 diabetes.

Deudomperidone is a novel formulation of a well-known dopamine D2/D3 antagonist. Deudomperidone was designed to improve safety while maintaining the efficacy of domperidone, which has both prokinetic and antiemetic effects with no anticholinergic activity.

There is a lack of safe, well-tolerated and chronic treatments for gastroparesis.

Metoclopramide, the only FDA-approved, short-term medicine in the U.S., carries a black box warning due to the risk of tardive dyskinesia as it crosses the blood brain barrier.
Domperidone is the first-line treatment outside of the U.S. and is available only for short-term use. Domperidone is not approved in the U.S. in part due to a perceived cardiovascular risk associated with QT prolongation.

Deudomperidone

Candidate

Pre-Clinical Phase 1 Phase 2 Phase 3

Deudomperidone

(CIN-102) - Phase 2

Deudomperidone (CIN-102) is an oral, small molecule dopamine D2/D3 receptor antagonist. As an antiemetic and prokinetic, deudomperidone improves gastric emptying and relieves the symptoms of nausea and vomiting associated with gastroparesis.

Deudomperidone has successfully completed its Phase 1 program, demonstrated a negative thorough QT study and conducted a proof-of-concept Phase 2 trial demonstrating a reduction in gastric emptying.

CinDome is currently enrolling the envision3D study for people who have diabetic gastroparesis.

CinDome Team

CinDome Pharma is a CinRx portfolio company. CinRx deploys a hub-and-spoke approach in advancing its portfolio of multiple biotechnology companies, each rapidly developing high-impact medicines for patients in need.

The CinDome team consists of the scientific, technical and clinical development experts from its central team at CinRx Pharma.

For more information about the CinRx model, to meet the team or to view the entire portfolio, visit CinRx.com.